Deutsche Bank AG Buys 15,481 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

Deutsche Bank AG raised its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 46.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 48,745 shares of the company's stock after acquiring an additional 15,481 shares during the period. Deutsche Bank AG owned about 0.08% of Rhythm Pharmaceuticals worth $2,729,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Crestline Management LP grew its position in shares of Rhythm Pharmaceuticals by 31.9% in the 4th quarter. Crestline Management LP now owns 25,062 shares of the company's stock valued at $1,403,000 after purchasing an additional 6,064 shares during the period. Bridgefront Capital LLC bought a new position in Rhythm Pharmaceuticals in the fourth quarter valued at approximately $258,000. Balyasny Asset Management L.P. bought a new position in Rhythm Pharmaceuticals in the fourth quarter valued at approximately $7,746,000. Bellevue Group AG boosted its holdings in shares of Rhythm Pharmaceuticals by 50.3% in the fourth quarter. Bellevue Group AG now owns 23,596 shares of the company's stock valued at $1,321,000 after buying an additional 7,896 shares during the period. Finally, BNP Paribas Financial Markets increased its position in shares of Rhythm Pharmaceuticals by 491.0% during the fourth quarter. BNP Paribas Financial Markets now owns 85,249 shares of the company's stock worth $4,772,000 after acquiring an additional 70,824 shares in the last quarter.

Insider Buying and Selling at Rhythm Pharmaceuticals

In other news, insider Pamela J. Cramer sold 20,760 shares of Rhythm Pharmaceuticals stock in a transaction dated Tuesday, April 8th. The shares were sold at an average price of $60.14, for a total transaction of $1,248,506.40. Following the completion of the transaction, the insider now directly owns 19,209 shares in the company, valued at $1,155,229.26. This trade represents a 51.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Yann Mazabraud sold 6,745 shares of the company's stock in a transaction dated Tuesday, April 29th. The stock was sold at an average price of $65.08, for a total transaction of $438,964.60. Following the completion of the sale, the executive vice president now owns 37,655 shares in the company, valued at $2,450,587.40. This represents a 15.19% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 127,630 shares of company stock worth $7,107,346. 6.10% of the stock is owned by corporate insiders.

Rhythm Pharmaceuticals Trading Down 5.1%

Rhythm Pharmaceuticals stock traded down $3.18 during midday trading on Tuesday, reaching $59.18. The stock had a trading volume of 630,928 shares, compared to its average volume of 555,676. The company has a fifty day moving average price of $59.07 and a two-hundred day moving average price of $57.60. Rhythm Pharmaceuticals, Inc. has a 12 month low of $35.17 and a 12 month high of $68.58. The company has a market capitalization of $3.77 billion, a P/E ratio of -13.67 and a beta of 2.36.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.12). Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%. The firm had revenue of $37.72 million for the quarter, compared to the consensus estimate of $40.43 million. During the same quarter in the prior year, the firm earned ($2.35) EPS. The company's revenue was up 25.9% compared to the same quarter last year. On average, equities research analysts predict that Rhythm Pharmaceuticals, Inc. will post -4.32 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

RYTM has been the topic of several research reports. Bank of America raised shares of Rhythm Pharmaceuticals from a "neutral" rating to a "buy" rating and set a $63.00 price objective on the stock in a research report on Monday, April 7th. Needham & Company LLC lifted their price target on Rhythm Pharmaceuticals from $66.00 to $72.00 and gave the company a "buy" rating in a research note on Wednesday, May 7th. Canaccord Genuity Group upped their price objective on Rhythm Pharmaceuticals from $81.00 to $92.00 and gave the stock a "buy" rating in a research report on Tuesday, April 8th. Stifel Nicolaus initiated coverage on Rhythm Pharmaceuticals in a research report on Wednesday, March 5th. They issued a "buy" rating and a $78.00 target price on the stock. Finally, Morgan Stanley reaffirmed an "overweight" rating and set a $72.00 price target on shares of Rhythm Pharmaceuticals in a research report on Friday, March 7th. Thirteen research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $75.38.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.